Karyopharm Therapeutics (KPTI) Q3 2024 earnings summary

Executive summary

• Reported third consecutive quarter of U.S. XPOVIO net product revenue growth, reaching $29.5 million in Q3 2024, with global expansion and approvals in over 45 countries.

• Advanced pivotal phase III trials in myelofibrosis, endometrial cancer, and multiple myeloma, with regulatory and clinical milestones on track and updated endpoints following FDA discussions.

• Net loss for Q3 2024 was $32.1 million, an improvement from $34.5 million in Q3 2023; YTD net loss narrowed to $45.6 million, aided by a $44.7 million debt extinguishment gain.

• Substantial doubt exists regarding the ability to continue as a going concern beyond Q4 2025 without additional funding.

• Potential for $2 billion annual U.S. peak revenues across key indications, driven by innovative mechanisms and unmet medical needs.

Financial highlights

• Q3 2024 total revenue was $38.8 million, up from $36.0 million in Q3 2023; YTD 2024 revenue reached $114.7 million.

• U.S. XPOVIO net product revenue for Q3 2024 was $29.5 million, a 2% decrease year-over-year but a 5% increase sequentially from Q2 2024.

• License and other revenue increased to $9.3 million in Q3 2024, primarily due to $6.0 million in milestone revenue from Menarini.

• Cash, cash equivalents, and investments totaled $133.9 million as of September 30, 2024, down from $192.4 million at year-end 2023.

• Net loss for Q3 2024 was $32.1 million ($0.26 per share), compared to $34.5 million ($0.30 per share) in Q3 2023.

Outlook and guidance

• Full-year 2024 total revenue guidance narrowed to $145–$155 million; U.S. XPOVIO net product revenue guidance set at $110–$115 million.

• R&D and SG&A expenses expected at $255–$265 million, including $20 million in non-cash stock-based compensation.

• Cash runway expected to fund operations into Q1 2026, or Q4 2025 after debt repayments and liquidity covenants.

• 2025 operating expenses projected to be lower than 2024 due to cost-saving initiatives.

• Net product revenue is expected to remain consistent in Q4 2024 compared to Q3 2024.